49 results about "Genitourinary system" patented technology

The present invention generally relates to the field of prostheses for surgical applications, to methods of their manufacturing and to methods of treating a patient by implanting them into a patient. More particularly, the present invention relates to prostheses having a multi-layered sheet structure and their use in hernia repair, the repair of anatomical defects of the abdominal wall, diaphragm, and chest wall, correction of defects in the genitourinary system, and repair of traumatically damaged organs such as the spleen, liver or kidney.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

The invention discloses an application of a compound as a JAK-STAT3 signal passage inhibitor, and particularly relates to an application of a compound with a formula I or pharmaceutically acceptable salt of the compound in the process of preparing an anti-tumor medicament. The application provides a novel treating candidate medicament for a tumor patient, thereby probably further improving the treatment effect on the patient and improving the prognosis of the patient. The compound with the formula I or the pharmaceutically acceptable salt of the compound has the effect on various tumor cells, which indicates that the compound can be used for treating various cancers including cerebral tumor, genitourinary system tumor, lymphatic system tumor, stomach cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, bone cancer, blood cancer, leukemia, breast cancer and histiocytic lymphoma, non-small cell lung cancer, small-cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, pancreatic cancer, prostatic cancer, liver cancer, epithelial cell cancer and the like. The definition of genes in the formula refers to description for details.

The invention relates to a cefathiamidine hydrate and a preparation method and application thereof. The crystalline hydrate has high storage stability, is suitable for preparing bacteria sensitive to Gram-positive or negative bacteria, and is applied to the preparation of medicaments for treating or preventing infection of respiratory systems, liver and gall bladder systems, five sense organs, urogenital systems, bones, joints and skin soft tissues as well as diseases such as endocarditis, septicemia, brain fever and the like of human beings or animals caused by bacteria which are sensitive to Gram-positive or negative bacteria.

Implantable drug delivery devices are provided lo have a deployment shape for implantation in the body and a retention shape for retention in the body. The device may have one or more elongated drug reservoirs containing a drug, mid the drug reservoir may be formed from a deformable material. In one case, a first filament is attached to the first end of the drug reservoir and second filament is attached to the second end of the drug reservoir, wherein a fastener is positioned about the first and second filaments to permit shortening and prevent lengthening of the filaments with reference to the ends of the daig reservoir, as a means for transforming the device from the implantation shape to the retention shape.

The invention relates to a method for preparing a genitourinary system tumor cell ferroptosis model based on ferric ammonium citrate and application in preparation of antitumor drugs, and belongs to the technical field of antitumor drugs. The invention provides the method for preparing the genitourinary system tumor cell ferroptosis model based on ferric ammonium citrate. The method comprises thefollowing steps: when the density of cultured tumor cells reaches 65-75%, adding ferric ammonium citrate, and continuing to culture for 20-30 hours to obtain the ferroptosis model. The way of treatinggenitourinary system tumor cells by using the ferric ammonium citrate is a very simple, convenient and efficient method for preparing the a ferroptosis tumor cell model, and the anti-tumor activity of the ferric ammonium citrate provides a theoretical basis for subsequent research and development and clinical treatment.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition capable of tonifying the kidneys. The traditional Chinese medicine composition is prepared from Chinese yams, angelica sinensis, chuanqiong rhizome, glossy privet fruits, radix polygoni multiflori, rhizoma cibotii, radix cynanchi paniculati, semen cuscutae, human placenta, fructus foeniculi, ginseng, corn cervi pantotrichum, milkvetch roots, wolfberry fruits, herba leonuri, fructus schisandrae chinensis, poria cocos, rhizoma atractylodis macrocephalae, rhizoma et radix notopterygii, herba asari, penis cervi, capillary wormwood herbs, endothelium corneum gigeriae galli, hippocampi, manyflower solomonseal rhizome, cassia seeds, herba taxilli, kudzuvine roots, jujubes, arillus longan, radix et rhizoma rhei, cortex eucommiae, lilies, Chinese thorowax roots, herba houttuyniae and isatis roots. The traditional Chinese medicine composition is used for regulating Qi and blood circulation of kidneys and kidney channels or organs and tissue such as related urinary and reproductive systems of which the functions are related with the kidneys, the effect of tonifying the kidneys is fast, toxic and side effects on a human body do not exist, and the treatment effect is good. Compared with congeneric drugs, the traditional Chinese medicine composition has the advantages of being rigorous in compatibility, mild in drug property and significant in curative effect, and large-area application and promotion on clinic are convenient.

Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

The invention belongs to the technical field of drug preparation, and particularly relates to a preparation method of a drug intermediate for an urogenital system. 2-amino terephthalic acid and nickelchloride hexahydrate serve as raw materials, a metal organic skeleton structure is formed, then the metal organic skeleton structure is loaded with certain Pd, and finally a load type high-dispersionPd / Ni co-doped double-component catalyst is obtained through reduction at high temperature. The catalyst is adopted to catalyze 2-bromo-5-nitro-3-(trifluoromethyl)pyridine to be subjected to a cyanation reaction to prepare the drug intermediate 2-cyano-5-nitro-3-(trifluoromethyl)pyridine for the urogenital system, the yield is high, and post-treatment is simple, the high-purity target product canbe obtained by adopting extraction and concentration, and column chromatography purification is not needed; and the catalyst can be conveniently removed from the system, and can be recycled.